APGN [NASD]
Apexigen, Inc.
Index- P/E- EPS (ttm)-0.58 Insider Own2.40% Shs Outstand21.45M Perf Week-51.67%
Market Cap79.77M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float19.75M Perf Month-36.93%
Income-4.20M PEG- EPS next Q- Inst Own17.20% Short Float0.20% Perf Quarter-70.08%
Sales- P/S- EPS this Y- Inst Trans9.46% Short Ratio0.18 Perf Half Y-69.84%
Book/sh6.78 P/B0.45 EPS next Y- ROA-7.30% Target Price- Perf Year-69.42%
Cash/sh0.00 P/C797.70 EPS next 5Y- ROE-7.60% 52W Range3.25 - 31.35 Perf YTD-69.63%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-90.30% Beta-
Dividend %- Quick Ratio0.00 Sales past 5Y- Gross Margin- 52W Low-6.46% ATR1.11
Employees22 Current Ratio0.00 Sales Q/Q- Oper. Margin- RSI (14)31.21 Volatility28.05% 24.18%
OptionableYes Debt/Eq0.02 EPS Q/Q-536.90% Profit Margin- Rel Volume0.61 Prev Close3.36
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume223.93K Price3.04
Recom- SMA20-48.61% SMA50-62.03% SMA200-68.19% Volume137,065 Change-9.52%
Sep-12-22 08:38AM
Sep-10-22 08:00AM
Sep-07-22 08:01AM
Sep-05-22 08:00AM
Aug-31-22 06:25PM
08:43AM Loading…
Aug-08-22 08:43AM
Aug-04-22 08:00AM
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.